Clinical Edge Journal Scan

Risk of developing dementia is similar with tofacitinib, tocilizumab, or TNFi vs. abatacept in RA


 

Key clinical point: Treatment with tofacitinib, tocilizumab, or tumor necrosis factor inhibitors (TNFi) vs. abatacept did not reduce the risk of developing Alzheimer disease and related dementia (ADRD) in patients with rheumatoid arthritis (RA).

Major finding: The risk for ADRD associated with tofacitinib (adjusted hazard ratio [aHR] 0.90; 95% CI 0.55-1.51), tocilizumab (aHR 0.82; 95% CI 0.55-1.21), and TNFi (aHR 0.93; 95% CI 0.72-1.20) was similar to that with abatacept.

Study details: This was an observational study including 22,569 patients aged 65 years with RA from the DREAM study who were treated with tofacitinib, tocilizumab, or TNFi and were propensity score-matched with an equal number of patients treated with abatacept.

Disclosures: The DREAM study is funded by the National Institute on Aging . Several authors reported receiving grants, personal fees, or salary support from or owning stocks in various sources outside the submitted work.

Source: Desai RJ et al. Comparative risk of Alzheimer disease and related dementia among Medicare beneficiaries with rheumatoid arthritis treated with targeted disease-modifying antirheumatic agents. JAMA Netw Open. 2022;5(4):e226567 (Apr 8). Doi: 10.1001/jamanetworkopen.2022.6567

Recommended Reading

Clinical Edge Journal Scan Commentary: RA May 2022
MDedge Rheumatology
Parents’ autoimmune diseases may affect children’s development
MDedge Rheumatology
Upadacitinib earns FDA approval for ankylosing spondylitis 
MDedge Rheumatology
Reduced-frequency methotrexate monitoring causes no harm
MDedge Rheumatology
‘Goodie bag’ pill mill doctor sentenced to 2 decades in prison
MDedge Rheumatology
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
MDedge Rheumatology
RA: Upadacitinib plus elsubrutinib combo (ABBV-599) shows promise in phase 2
MDedge Rheumatology
Higher COVID-19 hospitalization risk in RA vs. general population despite vaccination
MDedge Rheumatology
Prognostic factors for mortality in rheumatoid arthritis-associated interstitial lung disease
MDedge Rheumatology
Poor prognostic joint locations in early RA may indicate rapidly progressing disease
MDedge Rheumatology